Denise Yardley, MD, sheds light on individualized treatment approaches and other key developments in HER2-positive breast cancer.
My Treatment Approach: HER2-Positive Breast Cancer
Joyce A. O'Shaughnessy, MD, sheds light on the current paradigm of HER2-positive breast cancer and the optimal role of neratinib in the early-stage and advanced settings.
Joyce A. O'Shaughnessy, MD, sheds light on the current paradigm of HER2-positive breast cancer and the optimal role of neratinib in the early-stage and advanced settings.
Adam M. Brufsky, MD, PhD, highlightes the treatment landscape in HER2-positive breast cancer, remaining sequencing questions, and the growing utility of neratinib in the paradigm.
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
3
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
4
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
5